[{"id":"04d8f3c7-64bd-44c3-be44-47d8879d4d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832892","created_at":"2023-04-27T14:05:02.983Z","updated_at":"2024-07-02T16:34:26.014Z","phase":"Phase 1/2","brief_title":"Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05832892","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • CTLA4 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • erfonrilimab (KN046) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-14"},{"id":"5216fc75-03db-4204-a70d-358dda4f246f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06023758","created_at":"2023-09-05T18:12:35.831Z","updated_at":"2024-07-02T16:35:04.409Z","phase":"Phase 2","brief_title":"Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC","source_id_and_acronym":"NCT06023758","lead_sponsor":"Peking University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • erfonrilimab (KN046) • anbenitamab (KN026)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-10"},{"id":"6843c310-89f3-4a46-822e-007bc52f641b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420220","created_at":"2022-06-15T15:55:24.895Z","updated_at":"2024-07-02T16:35:06.663Z","phase":"Phase 2","brief_title":"Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05420220","lead_sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • erfonrilimab (KN046)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":" Primary completion: 05/29/2027","primary_completion_date":" 05/29/2027","study_txt":" Completion: 12/26/2027","study_completion_date":" 12/26/2027","last_update_posted":"2024-05-01"},{"id":"62515fcb-d753-4019-96db-b94b15aec588","acronym":"","url":"https://clinicaltrials.gov/study/NCT04040699","created_at":"2021-01-17T17:35:46.592Z","updated_at":"2024-07-02T16:35:10.718Z","phase":"Phase 1","brief_title":"KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor","source_id_and_acronym":"NCT04040699","lead_sponsor":"Peking University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erfonrilimab (KN046) • anbenitamab (KN026)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 09/22/2022","primary_completion_date":" 09/22/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2024-04-09"},{"id":"fffc67bb-7fbb-40b0-9b45-301133ae28bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04984668","created_at":"2021-07-30T17:55:12.603Z","updated_at":"2024-07-02T16:35:19.910Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors","source_id_and_acronym":"NCT04984668","lead_sponsor":"Suzhou Kintor Pharmaceutical Inc,","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erfonrilimab (KN046) • ascrinvacumab (GT90001)"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-09"},{"id":"7fe8877d-c34b-47ad-b49c-85b43f276263","acronym":"","url":"https://clinicaltrials.gov/study/NCT06099821","created_at":"2023-10-25T19:14:05.391Z","updated_at":"2024-07-02T16:35:31.498Z","phase":"Phase 2","brief_title":"KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade","source_id_and_acronym":"NCT06099821","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • Stivarga (regorafenib) • erfonrilimab (KN046)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-26"},{"id":"892c4ecd-7891-464d-9a1b-14b7e90c33c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05985109","created_at":"2023-08-14T16:10:05.175Z","updated_at":"2024-07-02T16:35:31.592Z","phase":"Phase 2","brief_title":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05985109","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • oxaliplatin • irinotecan • erfonrilimab (KN046)"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 10/26/2023","start_date":" 10/26/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-26"},{"id":"bfd133ba-4207-42a9-a0dd-8e750a9eae6b","acronym":"HERCKER-01","url":"https://clinicaltrials.gov/study/NCT05985707","created_at":"2023-08-14T16:10:12.961Z","updated_at":"2024-07-02T16:35:39.614Z","phase":"Phase 2","brief_title":"KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma","source_id_and_acronym":"NCT05985707 - HERCKER-01","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2 • KRAS • BRAF","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • RAS wild-type • RAS wild-type + BRAF wild-type","tags":["HER-2 • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • erfonrilimab (KN046) • anbenitamab (KN026)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-08-21"}]